Travere Therapeutics won full approval for Filspari, which treats a rare autoimmune disease that affects the kidneys.
Filspari, also known as sparsentan, received an accelerated …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The revenue for Aflibercept Biosimilar is expected to reach an annual total of $146 mn by 2039 globally based off GlobalData’s Revenue Model. The drug’s
Societal issues -; including the growth in ultra-high-cost treatments, the epidemic of mental health and substance use disorders, climate change, and the rise of artificial
What You Should Know: – Veterans across the United States can now access convenient, on-demand healthcare through VA Health Chat, following the platform’s national rollout